Results 171 to 180 of about 14,163 (275)
The use of left ventricular ejection fraction in the diagnosis and management of heart failure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS)
European Journal of Heart Failure, EarlyView.Abstract
This clinical consensus statement revisits the role of left ventricular ejection fraction (LVEF) as a measurement of cardiac function, a prognostic marker and a major criterion to classify patients with heart failure, and gives new advice for clinical practice.Giuseppe M.C. Rosano, John R. Teerlink, Koichiro Kinugawa, Antoni Bayes‐Genis, Ovidiu Chioncel, James Fang, Barry Greenberg, Nasrien E. Ibrahim, Teruhiko Imamura, Takayuki Inomata, Koichiro Kuwahara, Brenda Moura, Anekwe Onwuanyi, Naoki Sato, Gianluigi Savarese, Yasuhiko Sakata, Nancy Sweitzer, Jane Wilcox, Kazuhiro Yamamoto, Marco Metra, Andrew J.S. Coats +20 morewiley +1 more sourceFinerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial
European Journal of Heart Failure, EarlyView.Finerenone and glycaemic status in patients with heart failure with mildly reduced/preserved ejection fraction. CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; RR, rate ratio. Abstract Aims
The efficacy and safety of the non‐steroidal mineralocorticoid receptor antagonist, finerenone, have not been examined in patients Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Meike Brinker, Patrick Schloemer, Prabhakar Viswanathan, Andrea Lage, Katja Rohwedder, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray +18 morewiley +1 more sourceConsequences of Amyloid‐β Deficiency for the Liver
Advanced ScienceThe hepatic content of amyloid beta (Aβ) decreases drastically in human and rodent cirrhosis highlighting the importance of understanding the consequences of Aβ deficiency in the liver.Gayane Hrachia Buniatian, Ute Schwinghammer, Roman Tremmel, Holger Cynis, Thomas S. Weiss, Ralf Weiskirchen, Volker M. Lauschke, Sonia Youhanna, Isbaal Ramos, Maria Valcarcel, Torgom Seferyan, Jens‐Ulrich Rahfeld, Vera Rieckmann, Kathrin Klein, Marine Buadze, Victoria Weber, Valentina Kolak, Rolf Gebhardt, Scott L. Friedman, Ulrike C. Müller, Matthias Schwab, Lusine Danielyan +21 moredoaj +1 more sourceBrain Neprilysin Activity and Susceptibility to Transgene-Induced Alzheimer Amyloids [PDF]
, 2005 Neprilysin (NEP) is a zinc metalloproteinase that degrades enkephalins, endothelins, and the Alzheimer’s disease amyloid ß (Aß) peptides. NEP-deficient mice possess increased levels of brain Aß1-40 and Aß1-42. The objective of this study was to determine Carter, Troy L., Ehrlich, Michelle E., Gandy, Sam, Ghiso, Jorge, Pedrini, Steve +4 morecore +1 more sourceAngiotensin receptor/Neprilysin inhibitor effects in CRTd non-responders: from epigenetic to clinical beside.
Pharmacological Research, 2022 C. Sardu, M. Massetti, L. Scisciola, M. Trotta, Matteo Santamaria, M. Volpicelli, V. Ducceschi, G. Signoriello, N. D’Onofrio, L. Marfella, F. Casolaro, M. D. Amico, A. Ruocco, M. Balestrieri, C. Mauro, C. Rafaniello, A. Capuano, G. Paolisso, R. Marfella +18 moresemanticscholar +1 more sourceMinimization or withdrawal of oral pharmacotherapy in chronic heart failure patients with improved myocardial function: A systematic review
European Journal of Heart Failure, EarlyView.This systematic review included seven studies that reported the outcomes of minimization or withdrawal of oral pharmacotherapy in chronic heart failure (HF) patients with improved myocardial function. There is a dearth of existing evidence, which supports only loop diuretic withdrawal and possibly carvedilol monotherapy.Yuxiang Luo, Wenbin Xiao, Yusuf Z. Sener, Wouter C. Meijers, Robert M.A. van der Boon, Elfatih A. Hasabo, Osama Soliman, Rudolf A. de Boer, Kadir Caliskan +8 morewiley +1 more sourceFerric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure (FAIR‐HF2‐DZHK05) trial: Baseline characteristics and comparison to other relevant clinical trials
European Journal of Heart Failure, EarlyView.Differences in baseline characteristics between major trials of intravenous (IV) iron therapy in heart failure. LVEF, left ventricular ejection fraction; SGLT2, sodium–glucose cotransporter 2. Aims
Prior randomized trials have reported conflicting evidence regarding the efficacy of intravenous (IV) iron in patients with heart failure with reduced ...Stefan D. Anker, Tim Friede, Javed Butler, Khawaja M. Talha, Marius Placzek, Monika Diek, Anna Nosko, Adriane Stas, Stefan Kluge, Dominik Jarczak, Geraldine Deheer, Meike Rybczynski, Antoni Bayes‐Genis, Frank Edelmann, Gerasimos Filippatos, Gerd Hasenfuß, Wilhelm Haverkamp, Mitja Lainscak, Ulf Landmesser, Iain C. Macdougall, Bela Merkely, Burkert M. Pieske, Fausto J. Pinto, Tienush Rassaf, Maurizio Volterrani, Stephan von Haehling, Markus S. Anker, Wolfram Doehner, Hüseyin Ince, Friedrich Koehler, Gianluigi Savarese, Ursula Rauch‐Kröhnert, Tommaso Gori, Teresa Trenkwalder, Ibrahim Akin, Christina Paitazoglou, Iwona Kobielusz‐Gembala, Witold Zmuda, Luca Kuthi, Norbert Frey, Manuela Licka, Stefan Kääb, Karl‐Ludwig Laugwitz, Piotr Ponikowski, Mahir Karakas +44 morewiley +1 more source8532 Circulating Neprilysin in Pregnancy
Journal of the Endocrine SocietyAbstract Disclosure: A. Kulovic-Sissawo: None. E. Weiss: None. E. Jantscher-Krenn: None. U. Hiden: None. Background: In the complex nature of pregnancy, the female organism undergoes pivotal vascular and metabolic changes orchestrated by a tightly regulated interplay of bioactive regulatory molecules.Kulovic-Sissawo, Azra, Weiss, Elisa, Jantscher-Krenn, Evelyn, Hiden, Ursula +3 moreopenaire +1 more sourceFinerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial
European Journal of Heart Failure, EarlyView.The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preserved ejection fraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status. BMI, body mass index; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Katharina Mueller, Markus F. Scheerer, Prabhakar Viswanathan, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray +16 morewiley +1 more source